ABVC BioPharma
ABVC
9 hedge funds and large institutions have $817K invested in ABVC BioPharma in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
168% more capital invested
Capital invested by funds: $305K → $817K (+$513K)
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.05% less ownership
Funds ownership: 2.21% → 2.16% (-0.05%)
10% less funds holding
Funds holding: 10 → 9 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$87.9K |
| 2 |
Renaissance Technologies
New York
|
+$56.8K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$24.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.19K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$65 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$30.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$12.2K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$10.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.02K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $248K | +$87.9K | +64,586 | +138% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $246K | +$8.19K | +6,017 | +6% |
|
|
XT
3
XTX Topco
George Town,
Cayman Islands
| $117K | -$10.6K | -7,814 | -13% |
|
|
4
Renaissance Technologies
New York
| $92.8K | +$56.8K | +41,706 | New |
|
|
5
Northern Trust
Chicago,
Illinois
| $82.6K | +$24.5K | +18,009 | +94% |
|
6
State Street
Boston,
Massachusetts
| $28.7K | – | – | – |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $1.07K | +$31 | +23 | +5% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $788 | -$3.02K | -2,222 | -86% |
|
|
9
Bank of America
Charlotte,
North Carolina
| $296 | +$65 | +48 | +56% |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$30.7K | -29,003 | Closed |
|
|
TSS
11
Two Sigma Securities
New York
| – | -$12.2K | -11,470 | Closed |
|
ABVC Hedge Fund Activity: Q2 2025 in Review
9 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q2 2025, worth a combined $817K — up 168% from $305K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ABVC and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $87.9K. The largest seller was UBS Group, exiting entirely with an estimated $30.7K sold.
- 9 institutional investors held ABVC BioPharma (ABVC) as of Q2 2025, down from 10 in Q1 2025.
- Funds reported $817K of ABVC BioPharma stock for Q2 2025, up 168% quarter-over-quarter.
- 1 fund opened new ABVC BioPharma positions in Q2 2025 and 2 closed out, a net change of -1 holder.
- The largest ABVC BioPharma buyer in Q2 2025 was Vanguard Group, an estimated $87.9K added.
- The largest ABVC BioPharma seller in Q2 2025 was UBS Group, an estimated $30.7K sold.
Based on aggregated 13F filings for Q2 2025.